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Conclusion: This represents the first time that patient-reported outcomes have been
reported in both COURAGE-like and non COURAGE-like patients exclusively
receiving a DES. Although there were no differences in clinical outcomes, marked
improvements in patient’s health status were observed 12 months after XIENCE V.
QoL significantly improved with the two groups behaving similarly over time. There
were consistent improvements in QoL across all angina burden cohorts with
improvements occurring early, being sustained for 1 year and most notable when angina
burdens were greatest. These data extend patient’s perspectives on the benefits of PCI.
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Background: The PRO Kinetic Energy is a thin strut (60 μm) cobalt chromium alloy
(L605) bare metal stent, which is completely coated with a thin layer of amorphous
silicon carbide PROBIO. The aim of this registry is to evaluate the clinical performance
of the PRO-Kinetic Energy stent system in a large patient population in standard
clinical care.
Methods: Between April 09, and November 09, 2010, 1’016 subjects presenting with
de-novo and re-stenotic coronary artery lesions were consecutively enrolled in this
international, multicentric ENERGY Registry. Primary safety endpoint was MACE
(composite of cardiac death, clinically driven TLR, myocardial infarction and acute
myocardial infarction) at six-month follow-up. Additional follow-up assessments are
defined in the protocol for 12 and 24 months. Quality of Life (EQ-5D) evaluation will
be performed in a subgroup on all follow-up intervals. Following subgroups were pre-
specified: diabetes, AMI, unstable angina, small vessel (< 2.75 mm) and elderly
patients (> 75 yrs).
Results: Seven hundred eighty-nine men (78%) with a mean age of 66 ± 12.5, ranging
from 27 - 96 years, were enrolled in 48 sites in 10 countries. The majority of the
subjects presented with hypertension (71%), hyperlipidemia (68%) smoker (31%),
diabetes (16%). Fourteen percent of the patients experienced unstable angina. ACS
due to MI was seen in 452 patients. The portion of elderly patients is represented by
19%. Type A (21%), B1 (40%), B2 (29%) and C (10%) lesions were seen in this cohort.
Eighty-six percent (874/1016) follow up compliance at six-month follow-up was
achieved. MACE (hierachical) occurred in 4.7% subjects between baseline and 6-
month follow-up including 2.5% target lesion revascularizations,2.3% stent
thrombosis, 1.5% myocardial infarctions (incl. AMI) and 0.7% cardiac death.
Conclusion: New generation bare metal stents (BMS) like the PRO-Kinetic Energy
with very thin struts and passive coating show a very low rate of MACE compared to
previous BMS. Utility of such modern BMS platforms are still very relevant in the era
of DES.
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Background: The minimally invasive direct coronary artery bypassing (MIDCAB)
has proven its superiority over bare metal stenting of proximal left anterior descending
(LAD) artery in reducing the need of repeated revascularizations. Nevertheless, the
long term outcome of percutaneous coronary intervention (PCI) utilizing new
generation of drug eluting stenting (DES), in this lesion subset is unknown.
Methods: This is a multicenter retrospective registry of 463 consecutive patients,
enrolled between 2004 and 2009 with proximal, significant, type B and C LAD lesion
(>70% DS) who underwent either PCI with exclusive use of DES (72% of 2nd.
generation) or MIDCAB. We excluded patients with myocardial infarction (MI) on
admission, concomitant lesions in the right and/or circumflex coronary arteries,
previous PCI within 6 months, or previous CABG . A propensity score was utilized
for patients baseline characteristics matching and results adjustment.
Results: One hundred and eighty seven patients underwent PCI with DES while 276
MIDCAB. Patients in PCI group were older (63,6 ± 9,3 vs. 59,7 ± 10,2 y.o.; p<0,05),
more often female (32 vs. 21%; p<0,01) had higher CCS class (2,53 ± 0,9 vs. 2 ± 0,3;
p<0,01), higher Euroscore (4 vs. 2,2; p<0,01) and more often presented with peripheral
artery disease (8 vs. 2%; p<0,01). At 30 day follow up there was no death in both
groups. There were also no differences in the occurrence of major adverse
cardiovascular and cerebral events (MACCE) defined as death, stroke, myocardial
infarction or repeated revascularization between PCI and MIDCAB groups (0% vs.
0,7%;p=0,22). However there were less serious adverse events (SAE) defined as atrial
fibrillation, wound infection, low output syndrome or serious bleeding in patients who
underwent MIDCAB (0 vs. 5%; p<0,01). After adjustment at 5 year follow up there
were no differences in survival (93,5 vs. 95,7%; p=0,56), MACCE free survival (64,9
vs. 74,4%, p=0,12) and MI – free survival (94,9 vs. 95.8%; p=0,46) between PCI and
MIDCAB respectively. There was significantly higher freedom from repeated
revascularization in patients who underwent MIDCAB (86,4 vs. 64,1%; p=0,01).
Conclusion: Both procedures show exceptional safety, with no deaths and only minor
adverse events rate at periprocedural period. At long term PCI with DES is non inferior
to MIDCAB with regard to safety endpoints. The rate of repeated revascularizations
remained higher in the PCI group
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Background: Drug eluting stents (DES) of the first and second generation, differ in
their coating material which may have implications for the incidence of periprocedural
myocardial infarction (PMI). Our aim was to compare the incidence of PMI using the
revised Academic Research Consortium (ARC) definition of PMI between Taxus
Liberté, Endeavor Sprint, Endeavor Resolute and Xience V.
Methods: We assessed 800 patients treated with first (Taxus Liberté or Endeavor) or
second generation DES (Xience V or Resolute). Each DES group consisted of 200
consecutive patients, who were treated during the transition from first to second
generation DES. Routine peri-interventional assessment of cardiac biomarkers was
performed to compare the incidence of PMI between DES groups according to ARC:
2x upper reference limit of creatine kinase (CK), confirmed by CK-MB elevation.
Results: In 800 patients, a total of 1522 DES (363 Taxus; 385 Endeavor; 382 Xience
V; 392 Resolute) were implanted to treat 1232 lesions. Patient characteristics did not
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differ between groups. In patients receiving second generation DES, more multivessel
PCI were performed (p=0.01). The overall incidence of PMI was 4.75%. Between first
and second generation DES, there was no significant difference in PMI (5.5% vs.4.0%;
p=0.29). In a multivariate analysis, only the total number of stents implanted (p<0.001)
and presentation with acute coronary syndrome (p=0.02) were independent predictors
of PMI.
Table 1. Cardiac biomarkers for each DES type and DES generation. Values are
mean±SD, numbers of patients (percentage). 
CK = creatine kinase; DES = drug-eluting stents.
Conclusion: Using the revised ARC definition of PMI, there was no significant
difference in PMI between first and second generation DES following routine clinical
PCI.
TCT-202
The Difference of Predictors for Occurrence of Instent Restenosis in the under-
expanded or non under-expanded post-DES implantation : An intravascular
ultrasound analysis from multicenter, randomized trials
Ki-Woon Kang1, Byeong-Keuk Kim1, Young-Guk Ko1, Dong-Ho Shin1, Jung-Sun
Kim1, Donghoon Choi1, Yangsoo Jang1, 2, Myeong-Ki Hong1, 2
1Severance Cardiovascular Hospital, Seoul, Republic of Korea; 2Severance
Biomedical Science Institute, Seoul, Republic of Korea
Background: Stent underexpansion (SUE), defined by minimal stent CSA (MSA < 5
mm2), is the one of the most important predictor of in-stent restenosis (ISR) in the era
of drug-eluting stent (DES) implantation. However, the difference of predictors for
occurrence of ISR between SUE and non-SUE might not be well known.
Methods: The EXCELLENT and POET were a multicenter, randomized trial
comparing paclitaxel-eluting stent (PES) (n=121), sirolimus-eluting stent (SES),
zotarolimus-eluting stent (ZES) and everolimus-eluting stent (EES) in patients with
stable or unstable angina. Angiographically ISR at follow-up was observed in 450
lesions treated with DES implantation. A total 393 of enrolled patients who underwent
post-intervention and 9-month follow-up IVUS investigation were followed clinically
for 3-year period (PES n=121, SES n=161, ZES n=59, EES n=52). We classified these
into 2 groups based on the MSA; SUE group (n=107, MSA < 5 mm2) vs. non-SUE
group (n=286, MSA ≥ 5 mm2).
Results: Significant intimal hyperplasia (IH) was defined as IH area more than 50%
area of stent. Overall, 25 lesions (23.3%) among SUE group had IVUS-defined ISR,
whereas 30 lesions (10.4 %) among non-SUE group has IVUS-defined ISR (p=0.005).
Multivariate logistic regression for the determinant for the IVUS-defined ISR in the
each groups were compared. In SUE group, diabetes mellitus [odd ratio (OR) =3.03,
confidence interval (CI) =1.10-8.39, p=0.0014] and long stent (> 28mm) (OR = 3.9,
CI = 1.2-12.6, p=0.017) were predictors for IVUS-defined ISR, however in non-SUE
group, diabetes mellitus (OR = 2.99, CI = 1.29-6.92, p=0.014) and age (OR = 1.24, CI
= 1.02-2.56, p=0.017) were predictors for IVUS-defined ISR at follow-up.
Conclusion: The difference of predictors for occurrence of ISR at follow-up might
exist between SUE and non-SUE group. However, in general, diabetes mellitus showed
a universal predictor for occurrence of ISR at follow-up regardless of under-expansion
after DES implantation.
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Background: Previous studies have demonstrated similar outcomes over the short to
mid-term in patients treated with paclitaxel-eluting stents (PESs) or sirolimus-eluting
stents (SESs). However there is limited ‘real-world’ data investigating long term
outcomes. This study compared outcomes at 5 years following revascularisation in the
two patient groups.
Methods: 4252 consecutive patients underwent PCI with either paclitaxel-eluting
(PES) or sirolimus-eluting stents (SES) at a single centre (October 2003 – January
2011). Indications for PCI included stable and unstable angina. Left main and vein
graft lesions were excluded. Demographic and procedural data were collected at the
time of intervention. All-cause mortality data were obtained from the Office of National
Statistics via the BCIS/CCAD national audit out to a median of 4.0 years (CI 2.4 – 5.6
years). Primary end point was major adverse cardiac events (MACE), a composite of
all-cause mortality, myocardial infarction and target vessel revascularization (TVR).
Results: There were 1592 (37%) patients treated with SES and 2,660 (63%) patients
treated with PES. Baseline demographic, angiographic, and procedural characteristics
were similar between the two groups. At 5 years there were no statistical differences
in MACE between the stent types (SES 15.9% 95% CI 12.7-19.4 vs. PES: 16.5% 95%
CI 12.6-20.3, p=0.9). This consisted of similar rates of all-cause mortality (10.1% vs.
9.3%, p=0.4), TVR (5.3% vs. 6.4%, p=0.4), and stent thrombosis (2% vs. 1.8%, p=0.5).
In diabetic patients (n=1172 (28%)), there was a trend towards lower MACE favouring
PES but this did not reach statistical significance (19% vs. 24%, p=0.16).
Conclusion: This observational analysis of PES and SES-treated patients demonstrates
similar overall safety and efficacy over a 5-year follow-up period with low rates of
TVR.
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